Omeros Corporation (OMER) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profit rebound ⢠Weak cash flow ⢠Heavy leverage OMER posted a sharp quarterly profit rebound and strong liquidity, but weak cash generation, negative equity, and heavy debt keep the turnaround high risk.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Failed support ⢠Weak base Support Level: $9.79 Resistance Level: $10.16-$10.26; stronger overhead resistance at $10.72-$11.15 OMER remains in a strong downtrend after a roughly 33% drop from its recent high, with lower highs/lows and failed support breaks keeping the technical setup weak unless it reclaims $10.16-$10.26 and then $10.72-$11.15.
Sentiment & News
Key News Insights: ⢠Launch traction ⢠Profit surprise ⢠Sentiment improving Omeros is showing early commercial traction from YARTEMLEA's U.S. launch, with Q1 2026 sales growth, strong profitability, and improving analyst sentiment.
AI Summary
OMER has shifted from a pure cash-burning biotech to an early commercial story thanks to YARTEMLEA's initial sales traction and high-margin economics, but the investment case remains fragile because negative cash flow, meaningful leverage, and weak price action mean the stock needs several more quarters of durable adoption and cash conversion before it deserves a sustained re-rating.
Description
Omeros Corporation is a commercial-stage biopharmaceutical company that develops small-molecule and protein therapeutics for inflammation, complement-mediated disorders, immune-related cancers, and addictive or compulsive disorders. Its pipeline spans late-stage assetsâmost notably a MASP-2 antibody that has completed a pivotal study for HSCTâTMA and is in Phase III for IgA nephropathy and aHUSâthrough earlier clinical programs and preclinical work on MASP-targeted small molecules, longer-acting antibodies, GPCR targets, and cell therapies. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | OMER | Omeros Corporation | Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026. | Closed | -7.1% |